Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. sambafun

SAMBAfun SIGNED

System for AcceleroMeter-Based Assessment of cardiac FUNction

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 SAMBAfun project word cloud

Explore the words cloud of the SAMBAfun project. It provides you a very rough idea of what is the project "SAMBAfun" about.

patented    leads    berlin    track    appear    accurate    routinely    smes    cardiac    models    surgery    lower    accuracy    market    standard    marker    surgeons    brings    heart    perioperative    myocardial    24h    soon    severe    contractility    economic    device    whereas    sambafun    undergoing    opinion    invasiveness    distributors    escape    accessibility    osypka    german    ipr    ties    biosignal    functioning    sme    complementary    input    hospitals    surgeries    accelerometer    offs    nurses    trusted    extensive    monitor    profile    certification    continuous    positions    latest    time    detect    days    hospitalization    patients    complications    data    cardiaccs    complication    detection    morbidity    risk    mortality    adding    quality    aarhus    surgical    axis    trade    motion    events    dominates    chain    turn    function    oslo    alert    health    analysed    leader    monitoring    reimbursement    regulatory    life    credible    solution    global    technologies    cardisense    markets    picked    epicardial    post    pace   

Project "SAMBAfun" data sheet

The following table provides information about the project.

Coordinator		 CARDIACCS AS 

Organization address
address: Maridalsveien 71B
city: Oslo
postcode: 458
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Norway [NO]
 Total cost 3˙688˙711 €
 EC max contribution 2˙918˙312 € (79%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-EIC-FTI-2018-2020
 Funding Scheme IA
 Starting year 2018
 Duration (year-month-day) from 2018-12-01   to  2021-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CARDIACCS AS NO (Oslo) coordinator 1˙107˙221.00
2    OSYPKA AG DE (RHEINFELDEN BADEN) participant 690˙375.00
3    AARHUS UNIVERSITET DK (AARHUS C) participant 487˙312.00
4    OSLO UNIVERSITETSSYKEHUS HF NO (OSLO) participant 454˙903.00
5    DEUTSCHES HERZZENTRUM BERLIN DE (BERLIN) participant 178˙500.00

Map

 Project objective

In patients undergoing open-heart surgeries, perioperative cardiac monitoring is used to track the functioning of the heart and identify complications. However, myocardial failure and other severe complications can escape detection using current monitoring technologies, given the trade-offs between invasiveness, real time measurements, accessibility and accuracy of data. Given the high-risk profile of these surgeries, failure to timely detect complications leads to increased mortality and morbidity, which in turn results in increased hospitalization costs and lower quality of life for the affected patients.

For effective cardiac monitoring, surgeons need real time data, 24h continuous monitoring during and post-surgery, and an accurate biosignal marker that can be trusted for immediate detection and assessment of cardiac events. No current technology enables this with low invasiveness and risk.

Cardiaccs (SME) and Osypka (SME) will bring to market a patented solution that involves adding a 3-axis accelerometer to a standard epicardial pace lead, which is routinely used for most cardiac surgical patients, to assess cardiac motion and contractility in real time, both during and after surgery – and up to 7 days. Data from CardiSense will appear on a monitor and an alert function will let surgeons and nurses know as soon as a complication is picked-up on the continuously analysed data.

SAMBAfun brings together 2 SMEs with complementary know-how, IPR and value chain positions. Cardiaccs patented the concept, whereas Osypka has 40 years of experience in developing cardiac pace leads. Osypka dominates the German market and has extensive ties to global distributors. Three leading research hospitals (Oslo, Aarhus and Berlin) will demonstrate the latest advances in this device, provide Key Opinion Leader input and contribute with multi-market, highly credible data for regulatory certification and health economic models to support reimbursement applications in all markets.

 Deliverables

List of deliverables.
Website Websites, patent fillings, videos etc. 2020-03-06 19:00:23

Take a look to the deliverables list in detail:  detailed list of SAMBAfun deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SAMBAFUN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SAMBAFUN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.1.)

Bio-LP-1 (2020)

A novel rapid environmental test for the human pathogen Legionella

Read More  

PATH-TOX (2018)

Artificial Intelligence to transform Drug and Chemical safety testing

Read More  

SAMBAfun (2018)

System for AcceleroMeter-Based Assessment of cardiac FUNction

Read More